Quick Answer
Inhibrx Biosciences, Inc. reported Stockholders Equity of $7.99 million for fiscal year 2025.
Inhibrx Biosciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $7.99M | -94.0% |
| 2024 | $133.58M | +207.1% |
| 2023 | $43.50M | -25.1% |
| 2022 | $58.06M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $36.83M | -79.4% | -46.3% |
| June 30, 2025 | $68.56M | -68.7% | -27.4% |
| March 31, 2025 | $94.44M | +716.4% | -29.3% |
| December 31, 2024 | $133.58M | +207.1% | -25.1% |
| September 30, 2024 | $178.47M | +37.7% | -18.6% |
| June 30, 2024 | $219.37M | +984.1% | +1796.3% |
| March 31, 2024 | $11.57M | -23.6% | -73.4% |
| December 31, 2023 | $43.50M | -25.1% | -66.4% |
- Inhibrx Biosciences, Inc. showed a decrease of -94.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Inhibrx Biosciences, Inc.’s stockholders equity has declined by 86.2% (from $58.06 million to $7.99 million).
- The most recent figure is from Inhibrx Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: